This article is more than 5 years old. Information may no longer be current.
FDA approves non-invasive therapy for glioblastoma
The FDA announced approval of the NovoTTF-100A System for the treatment of adult patients with glioblastoma multiforme brain tumors, following tumor recurrence and treatment with chemotherapy. The six-pound, portable, wearable device delivers an anti-mitotic, anti-cancer therapy.
“Recurrent glioblastoma multiforme is a devastating form of brain cancer that often eludes standard treatments,” Jeffrey Shuren, MD, JD, director of the FDA’s Center for Devices and Radiological Health, said in a press release. “The agency’s approval of the NovoTTF-100A System shows FDA’s commitment to innovative new devices that provide patients with other treatment options.”
|
|
In March, the FDA Neurological Devices Advisory Panel of the Medical Devices Advisory Committee voted 7 to 3 in favor of the device. Approval is based on results of a phase 3 trial that demonstrated comparable OS rates between patients treated with the NovoTTF-100A System (NovoCure) and those who underwent chemotherapy.
The device was also associated with improved quality of life compared with chemotherapy, according to a survey of patients in the study.
Patients should not use the NovoTTF-100A System if they have an implanted medical device or a skull defect, or have a known sensitivity to conductive hydrogels, such as those used with electrocardiograms, the FDA wrote in the release. The NovoTTF-100A System is not intended to be used in combination with other cancer treatment; the device should only be used after other treatments have failed.
 |
Follow HemOncToday.com on Twitter. |